Astria Therapeutics Inc (NASDAQ:ATXS) price on Friday, June 13, rose 2.14% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $5.72.
A look at the stock’s price movement, the close in the last trading session was $5.60. Turning to its 52-week performance, $12.92 and $3.56 were the 52-week high and 52-week low respectively. Overall, ATXS moved 44.08% over the past month.
Astria Therapeutics Inc’s market cap currently stands at around $322.80 million, with investors looking forward to this quarter’s earnings report slated for in July.
2 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 2 recommend ATXS as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ATXS’s current price about 17.41% and 22.83% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 62.70, while 7-day volatility ratio is 2.53% and 5.67% in the 30-day chart. Further, Astria Therapeutics Inc (ATXS) has a beta value of 0.40, and an average true range (ATR) of 0.44. Analysts have given the company’s stock an average 52-week price target of $22.5, forecast between a low of $20 and high of $25. Looking at the price targets, the low is -249.65% off current price level while to achieve the yearly target high, price needs to move -337.06%. Nonetheless, investors will most likely welcome a -293.36% jump to $22.5 which is the analysts’ median price.
If we refocus on Astria Therapeutics Inc (NASDAQ:ATXS), historical trading data shows that trading volumes averaged 475.38K over the past 3 months. The company’s latest data on shares outstanding shows there are 56.43 million shares.
The 19.25% of Astria Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 84.70% of the company’s shares. Current price change has pushed the stock -36.02% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ATXS stock continues to rise going into the next quarter.
